Search Results

There are 240787 results for: content related to: Perspectives on allergen-specific immunotherapy in childhood: An EAACI position statement

  1. Basic Concepts for the Development of a Biosimilar Product: Experience with Omnitrope®, the First Ever Approved Similar Biopharmaceutical Product

    Modern Biopharmaceuticals: Recent Success Stories

    Alexander Berghout, Andreas Premstaller, Mark McCamish, Pages: 401–428, 2013

    Published Online : 23 APR 2013, DOI: 10.1002/9783527669417.ch18

  2. You have full text access to this OnlineOpen article
    Biosimilar agents in oncology/haematology: from approval to practice

    European Journal of Haematology

    Volume 86, Issue 4, April 2011, Pages: 277–288, Dietger Niederwieser and Stephan Schmitz

    Article first published online : 25 JAN 2011, DOI: 10.1111/j.1600-0609.2010.01566.x

  3. You have free access to this content
    Close collaboration between academia, industry and drug regulators is required in the development of allergen products for specific immunotherapy in children

    Allergy

    Volume 66, Issue 8, August 2011, Pages: 999–1004, I. Eichler and E. Sala Soriano

    Article first published online : 23 MAR 2011, DOI: 10.1111/j.1398-9995.2011.02582.x

  4. Contact dermatitis as an adverse reaction to some topically used European herbal medicinal products – part 1: Achillea millefolium–Curcuma longa

    Contact Dermatitis

    Volume 71, Issue 1, July 2014, Pages: 1–12, Gioacchino Calapai, Marco Miroddi, Paola L. Minciullo, Achille P. Caputi, Sebastiano Gangemi and Richard J. Schmidt

    Article first published online : 13 MAR 2014, DOI: 10.1111/cod.12222

  5. Clinical Trials—Collecting Safety Data and Establishing the Adverse Drug Reactions Profile

    Stephens' Detection and Evaluation of Adverse Drug Reactions: Principles and Practice, Sixth Edition

    John Talbot, Marianne Keisu, Lars Ståhle, Pages: 215–289, 2012

    Published Online : 30 JAN 2012, DOI: 10.1002/9780470975053.ch4

  6. You have free access to this content
    Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets

    British Journal of Pharmacology

    Volume 166, Issue 3, June 2012, Pages: 823–846, Peter J Bugelski and Pauline L Martin

    Article first published online : 8 MAY 2012, DOI: 10.1111/j.1476-5381.2011.01811.x

  7. Review article: biosimilars are the next generation of drugs for liver and gastrointestinal diseases

    Alimentary Pharmacology & Therapeutics

    Volume 38, Issue 8, October 2013, Pages: 914–924, M. Rinaudo-Gaujous, S. Paul, E. D. Tedesco, C. Genin, X. Roblin and L. Peyrin-Biroulet

    Article first published online : 3 SEP 2013, DOI: 10.1111/apt.12477

  8. Role of modeling and simulation in pediatric investigation plans

    Pediatric Anesthesia

    Volume 21, Issue 3, March 2011, Pages: 214–221, Efthymios Manolis, Tariq Eldirdiry Osman, Ralf Herold, Franz Koenig, Paolo Tomasi, Spiros Vamvakas and Agnes Saint Raymond

    Article first published online : 18 JAN 2011, DOI: 10.1111/j.1460-9592.2011.03523.x

  9. You have free access to this content
    Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets

    British Journal of Pharmacology

    Volume 166, Issue 3, June 2012, Pages: 806–822, Pauline L Martin and Peter J Bugelski

    Article first published online : 8 MAY 2012, DOI: 10.1111/j.1476-5381.2011.01812.x

  10. New pathway for qualification of novel methodologies in the European medicines agency

    PROTEOMICS - Clinical Applications

    Volume 5, Issue 5-6, June 2011, Pages: 248–255, Efthymios Manolis, Spiros Vamvakas and Maria Isaac

    Article first published online : 28 APR 2011, DOI: 10.1002/prca.201000130

  11. Methods to Derive Withdrawal Periods in the European Union

    Strategies for Reducing Drug and Chemical Residues in Food Animals: International Approaches to Residue Avoidance, Management, and Testing

    G. Johan Schefferlie, Stefan Scheid, Pages: 65–79, 2014

    Published Online : 11 AUG 2014, DOI: 10.1002/9781118872819.ch5

  12. Optimized Nonclinical Safety Assessment Strategies Supporting Clinical Development of Therapeutic Monoclonal Antibodies Targeting Inflammatory Diseases

    Drug Development Research

    Volume 75, Issue 3, May 2014, Pages: 115–161, Frank R. Brennan, Annick Cauvin, Jay Tibbitts and Alison Wolfreys

    Article first published online : 29 APR 2014, DOI: 10.1002/ddr.21173

  13. Application of Dried Blood Spot Sampling in Clinical Pharmacology Trials and Therapeutic Drug Monitoring

    Dried Blood Spots: Applications and Techniques

    Kenneth Kulmatycki, Wenkui Li, Xiaoying (Lucy) Xu, Venkateswar Jarugula, Pages: 216–228, 2014

    Published Online : 13 JUN 2014, DOI: 10.1002/9781118890837.ch19

  14. A fresh perspective on comparing the FDA and the CHMP/EMA: approval of antineoplastic tyrosine kinase inhibitors

    British Journal of Clinical Pharmacology

    Volume 76, Issue 3, September 2013, Pages: 396–411, Rashmi R. Shah, Samantha A. Roberts and Devron R. Shah

    Article first published online : 20 AUG 2013, DOI: 10.1111/bcp.12085

  15. Biosimilars: how similar?

    Internal Medicine Journal

    Volume 44, Issue 3, March 2014, Pages: 218–223, V. Strand and B. Cronstein

    Article first published online : 13 MAR 2014, DOI: 10.1111/imj.12292

  16. Establishing Maximum Residue Limits in Europe

    Strategies for Reducing Drug and Chemical Residues in Food Animals: International Approaches to Residue Avoidance, Management, and Testing

    Kornelia Grein, Isaura Duarte, Pages: 49–63, 2014

    Published Online : 11 AUG 2014, DOI: 10.1002/9781118872819.ch4

  17. Quality Assurance Requirements in Plasma Product Manufacture

    Production of Plasma Proteins for Therapeutic Use

    Joseph Bertolini, Neil Goss, John Curling, Pages: 381–401, 2012

    Published Online : 14 DEC 2012, DOI: 10.1002/9781118356807.ch28

  18. You have free access to this content
    Appendix 5: The New EU Risk Management Plan

    Pharmacovigilance Medical Writing: A Good Practice Guide

    Justina Orleans-Lindsay, Pages: 215–225, 2012

    Published Online : 19 JUN 2012, DOI: 10.1002/9781118301906.app5

  19. Quantification of insulin

    Diabetic Medicine

    Volume 31, Issue 3, March 2014, Pages: 375–376, M. Takayama, K. Yamauchi and T. Aizawa

    Article first published online : 16 FEB 2014, DOI: 10.1111/dme.12337

  20. You have full text access to this OnlineOpen article
    GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

    International Journal of Clinical Practice

    Volume 68, Issue 5, May 2014, Pages: 557–567, S. Brunton

    Article first published online : 6 FEB 2014, DOI: 10.1111/ijcp.12361